• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用 PCA 和 HCA 的 DSC、FT-IR 和 NIR 与化学计量学评估,用于在药用辅料存在的情况下估算口服抗糖尿病药物利拉利汀的化学稳定性。

DSC, FT-IR and NIR with Chemometric Assessment Using PCA and HCA for Estimation of the Chemical Stability of Oral Antidiabetic Drug Linagliptin in the Presence of Pharmaceutical Excipients.

机构信息

Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland.

Department of Biophysics, Faculty of Medicine, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland.

出版信息

Molecules. 2022 Jul 3;27(13):4283. doi: 10.3390/molecules27134283.

DOI:10.3390/molecules27134283
PMID:35807528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9268681/
Abstract

Pharmaceutical excipients should not interact with active substances, however, in practice, they sometimes do it, affecting the efficacy, stability and safety of drugs. Thus, interactions between active substances and excipients are not desirable. For this reason, two component mixtures of oral antidiabetic drug linagliptin (LINA) with four excipients of different reactivity, i.e., lactose (LAC), mannitol (MAN), magnesium stearate (MGS) and polyvinylpyrrolidone (PVP), were prepared in a solid state. A high temperature and a high humidity of 60 °C and 70% RH, respectively, were applied as stressors in order to accelerate the potential interactions between LINA and excipients. Differential scanning calorimetry (DSC) as well as Fourier transform infrared (FT-IR) and near infrared (NIR) spectroscopy were used to estimate the changes due to potential interactions. In addition, chemometric computation of the data with principal component analysis (PCA) and hierarchical cluster analysis (HCA) was applied to adequately interpret the findings. Of the excipients used in the present experiment, all of them were not inert in relation to LINA. Some of the interactions were shown without any stressing, whereas others were observed under high-temperature/high-humidity conditions. Thus, it could be concluded that selection of appropriate excipients for LINA is very important question to minimize its degradation, especially when new types of formulations with LINA are being developed and manufactured.

摘要

药用辅料不应与活性物质相互作用,但在实践中,它们有时会相互作用,从而影响药物的疗效、稳定性和安全性。因此,不希望活性物质与辅料之间发生相互作用。出于这个原因,将口服抗糖尿病药物利那列汀(LINA)与四种反应性不同的赋形剂(乳糖(LAC)、甘露醇(MAN)、硬脂酸镁(MGS)和聚乙烯吡咯烷酮(PVP))制备成固体混合物。分别采用高温(60°C)和高湿度(70%相对湿度)作为应激剂,以加速 LINA 和赋形剂之间潜在的相互作用。采用差示扫描量热法(DSC)以及傅里叶变换红外(FT-IR)和近红外(NIR)光谱法来评估潜在相互作用引起的变化。此外,还应用主成分分析(PCA)和层次聚类分析(HCA)对数据进行化学计量学计算,以充分解释研究结果。在本实验中使用的赋形剂中,没有一种对 LINA 是惰性的。有些相互作用在没有任何应激的情况下表现出来,而另一些则在高温/高湿条件下观察到。因此,可以得出结论,选择合适的 LINA 赋形剂对于最小化其降解非常重要,特别是在开发和制造新型 LINA 制剂时。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/e0f9eca9753a/molecules-27-04283-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/a308d2813411/molecules-27-04283-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/dffb5539477d/molecules-27-04283-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/fc572c948214/molecules-27-04283-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/33245d1df353/molecules-27-04283-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/8561826d408d/molecules-27-04283-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/b751f4b0defe/molecules-27-04283-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/0c9b84afaa45/molecules-27-04283-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/0ea78cb7fc3d/molecules-27-04283-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/ee6c3a1d2f0c/molecules-27-04283-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/d25af53630dc/molecules-27-04283-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/8328593ec2f1/molecules-27-04283-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/2e16d7538c7a/molecules-27-04283-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/e0f9eca9753a/molecules-27-04283-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/a308d2813411/molecules-27-04283-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/dffb5539477d/molecules-27-04283-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/fc572c948214/molecules-27-04283-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/33245d1df353/molecules-27-04283-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/8561826d408d/molecules-27-04283-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/b751f4b0defe/molecules-27-04283-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/0c9b84afaa45/molecules-27-04283-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/0ea78cb7fc3d/molecules-27-04283-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/ee6c3a1d2f0c/molecules-27-04283-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/d25af53630dc/molecules-27-04283-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/8328593ec2f1/molecules-27-04283-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/2e16d7538c7a/molecules-27-04283-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5b/9268681/e0f9eca9753a/molecules-27-04283-g013.jpg

相似文献

1
DSC, FT-IR and NIR with Chemometric Assessment Using PCA and HCA for Estimation of the Chemical Stability of Oral Antidiabetic Drug Linagliptin in the Presence of Pharmaceutical Excipients.应用 PCA 和 HCA 的 DSC、FT-IR 和 NIR 与化学计量学评估,用于在药用辅料存在的情况下估算口服抗糖尿病药物利拉利汀的化学稳定性。
Molecules. 2022 Jul 3;27(13):4283. doi: 10.3390/molecules27134283.
2
Comprehensive Insight into Chemical Stability of Important Antidiabetic Drug Vildagliptin Using Chromatography (LC-UV and UHPLC-DAD-MS) and Spectroscopy (Mid-IR and NIR with PCA).综合运用色谱(LC-UV 和 UHPLC-DAD-MS)和光谱(中红外和近红外与 PCA)技术深入研究重要抗糖尿病药物维格列汀的化学稳定性
Molecules. 2021 Sep 16;26(18):5632. doi: 10.3390/molecules26185632.
3
Quantification of Compatibility Between Polymeric Excipients and Atenolol Using Principal Component Analysis and Hierarchical Cluster Analysis.采用主成分分析和层次聚类分析量化聚合物辅料与阿替洛尔的相容性。
AAPS PharmSciTech. 2021 Nov 19;23(1):3. doi: 10.1208/s12249-021-02143-2.
4
Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods.LC-UV、LC-MS 和 FT-IR 法测定西他列汀的化学稳定性。
J Pharm Biomed Anal. 2019 Feb 5;164:789-807. doi: 10.1016/j.jpba.2018.11.023. Epub 2018 Nov 15.
5
Compatibility study between ketoprofen and pharmaceutical excipients used in solid dosage forms.酮洛芬与固体制剂中药用辅料的相容性研究。
J Pharm Biomed Anal. 2011 Sep 10;56(2):221-7. doi: 10.1016/j.jpba.2011.05.017. Epub 2011 May 23.
6
Evaluation of drug-excipient interaction in the formulation of celecoxib tablets.塞来昔布片制剂中药物-辅料相互作用的评估
Acta Pol Pharm. 2011 May-Jun;68(3):423-33.
7
DSC, TGA-FTIR and FTIR Assisted by Chemometric Factor Analysis and PXRD in Assessing the Incompatibility of the Antiviral Drug Arbidol Hydrochloride with Pharmaceutical Excipients.差示扫描量热法、热重分析-傅里叶变换红外光谱联用及化学计量因子分析和 X 射线粉末衍射在评估抗病毒药物盐酸阿比多尔与药用辅料不相容性中的应用。
Molecules. 2024 Jan 4;29(1):264. doi: 10.3390/molecules29010264.
8
Determination of Chemical Stability of Two Oral Antidiabetics, Metformin and Repaglinide in the Solid State and Solutions Using LC-UV, LC-MS, and FT-IR Methods.采用 LC-UV、LC-MS 和 FT-IR 方法测定两种口服抗糖尿病药物二甲双胍和瑞格列奈在固态和溶液中的化学稳定性。
Molecules. 2019 Dec 4;24(24):4430. doi: 10.3390/molecules24244430.
9
Compatibility study between acetylcysteine and some commonly used tablet excipients.乙酰半胱氨酸与一些常用片剂辅料的相容性研究
J Pharm Pharmacol. 1992 Jun;44(6):515-8. doi: 10.1111/j.2042-7158.1992.tb03657.x.
10
Compatibility studies of nateglinide with excipients in immediate release tablets.那格列奈与速释片辅料的相容性研究。
Acta Pharm. 2011 Jun;61(2):237-47. doi: 10.2478/v10007-011-0016-4.

引用本文的文献

1
Modafinil-excipient compatibility study using differential scanning calorimetry.使用差示扫描量热法进行莫达非尼-辅料相容性研究。
J Adv Pharm Technol Res. 2023 Apr-Jun;14(2):75-81. doi: 10.4103/japtr.japtr_663_22. Epub 2023 Apr 13.

本文引用的文献

1
Miscibility and Solubility of Caffeine and Theophylline in Hydroxypropyl Methylcellulose.咖啡因与茶碱在羟丙基甲基纤维素中的混溶性和溶解性
Pharmaceutics. 2021 Nov 2;13(11):1836. doi: 10.3390/pharmaceutics13111836.
2
Comprehensive Insight into Chemical Stability of Important Antidiabetic Drug Vildagliptin Using Chromatography (LC-UV and UHPLC-DAD-MS) and Spectroscopy (Mid-IR and NIR with PCA).综合运用色谱(LC-UV 和 UHPLC-DAD-MS)和光谱(中红外和近红外与 PCA)技术深入研究重要抗糖尿病药物维格列汀的化学稳定性
Molecules. 2021 Sep 16;26(18):5632. doi: 10.3390/molecules26185632.
3
DPP-4 Inhibition and the Path to Clinical Proof.
二肽基肽酶-4抑制作用与临床验证之路
Front Endocrinol (Lausanne). 2019 Jun 19;10:376. doi: 10.3389/fendo.2019.00376. eCollection 2019.
4
Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods.LC-UV、LC-MS 和 FT-IR 法测定西他列汀的化学稳定性。
J Pharm Biomed Anal. 2019 Feb 5;164:789-807. doi: 10.1016/j.jpba.2018.11.023. Epub 2018 Nov 15.
5
The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.二肽基肽酶-4 抑制剂在糖尿病心血管疾病管理中的作用;以利格列汀为例。
Cardiovasc Diabetol. 2018 Apr 18;17(1):59. doi: 10.1186/s12933-018-0704-1.
6
Excipient Stability in Oral Solid Dosage Forms: A Review.辅料在口服固体制剂中的稳定性:综述。
AAPS PharmSciTech. 2018 Jan;19(1):12-26. doi: 10.1208/s12249-017-0864-4. Epub 2017 Sep 11.
7
Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.格列汀类药物及其作用靶点二肽基肽酶 4:在血管疾病治疗中的意义。
Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):185-93. doi: 10.1093/ehjcvp/pvv044. Epub 2015 Nov 26.
8
Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.药物-赋形剂相容性筛选--热分析和光谱技术的作用。
J Pharm Biomed Anal. 2014 Jan;87:82-97. doi: 10.1016/j.jpba.2013.06.016. Epub 2013 Jun 21.
9
Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment.利拉鲁肽:在 2 型糖尿病治疗中的药理作用、疗效和安全性。
Diabetol Metab Syndr. 2013 May 22;5(1):25. doi: 10.1186/1758-5996-5-25.